The aim of this study was to qualitatively characterize MCP-4/CCL13 by Surface Enhanced Laser Desorption Ionization Time Of Flight Mass Spectrometry (SELDI-TOF-MSTM) in the serum of RCC patients undergoing high dose IL-2 immunotherapy. This evidence concerns the gene IL2 and renal cell carcinoma.